Skip to content

The Platform

A test is a moment. Intelligence is a trajectory.

Sentos BioMed is built in three layers — a product, a platform, and an intelligence layer — each one widening what measuring mCRP can do.

The three layers

Product → Platform → Intelligence

01

Product — the measurement.

The mCRP-ALISA™ kit: a specific, quantitative readout for the active form of CRP. This is where clinical and lab value begins.

02

Platform — the infrastructure.

One validated analyte, many formats and settings: microplate today; point-of-care and multiplex inflammatory panels in development. A consistent way to measure mCRP wherever inflammation is a question.

03

Intelligence — the trajectory.

With appropriate consent and governance, repeated mCRP measurements over time turn a single result into a longitudinal signal — the basis for monitoring inflammation, not just detecting it. This is the long-horizon vision of The Inflammation Intelligence Company.

The intelligence layer is a forward-looking vision dependent on data governance, regulatory approval, and clinical validation.

Pipeline

What's in development

ProgrammeDescriptionStage TODO: stages
mCRP-ALISA™ microplateCore competitive assay for serumLead — in development
Point-of-care formatSimplified, near-patient configurationResearch / roadmap
Multiplex inflammatory panelmCRP alongside complementary markersResearch / roadmap
Therapy-monitoring applicationsmCRP trajectories to support treatment decisionsExploratory research
Pipeline stages are indicative and subject to funding, validation, and regulatory milestones.

Defensibility

Five sources of durability

Written for partners and investors who ask what protects the position:

  1. 1

    Analyte ownershipbuilding the reference standard for measuring mCRP specifically.

  2. 2

    Intellectual propertya patent-pending portfolio spanning the aptamer composition, the assay method, and the kit; provisional filed in India, with a defined international strategy. TODO: current filing status for public display

  3. 3

    Clinical evidencea growing, cohort-backed body of validation, led by the platform's founding research.

  4. 4

    Manufacturing know-howreproducible aptamer chemistry and coated-plate processes refined for scale.

  5. 5

    Data-network effectsover time, longitudinal inflammation data compounds into an asset competitors can't easily replicate.